Sarcopenia, an age-related decline in skeletal muscle mass and function, dramatically
affects the life quality of elder people. In view of increasing life expectancy, sarcopenia …

Serum biomarkers in Duchenne muscular dystrophy (DMD) may provide deeper insights
into disease pathogenesis, suggest new therapeutic approaches, serve as acute read-outs …

Becker muscular dystrophy (BMD) is a variant of dystrophin deficiency resulting from DMD
gene mutations. Phenotype is variable with loss of ambulation in late teenage or late mid-life …

Dysfunction and wasting of skeletal muscle as a consequence of illness decreases the
length and quality of life. Currently, there are few, if any, effective treatments available to …

Myostatin is a secreted signaling molecule that normally acts to limit muscle growth. As a
result, there is extensive effort directed at developing drugs capable of targeting myostatin to …

Follistatin, a physiological inhibitor of myostatin, induces a dramatic increase in skeletal
muscle mass, requiring the type 1 IGF-I receptor/Akt/mTOR pathway. The aim of the present …

Transgenic overexpression of Galgt2 (official name B4Galnt2) in skeletal muscle stimulates
the glycosylation of α dystroglycan (αDG) and the up-regulation of laminin α2 and dystrophin …

Increasing size and strength of skeletal muscle represents a promising therapeutic strategy
for muscular disorders. One possible tool is the inhibition of Myostatin (Mstn), a major …

Duchenne's muscular dystrophy (DMD) is X-chromosome linked muscle wasting dis-ease. It
is caused by a mutation in the gene coding protein called dystrophin leading to premature …

Myostatin is a transforming growth factor-β family member that normally acts to limit skeletal
muscle growth. Myostatin gene (MSTN) knockout (KO) mice show possible effects for the …